Jci_page_head_homepage_01 Jci_page_head_homepage_02
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Brian J. Druker, Nicholas B. Lydon
Published in Volume 105, Issue 1
J Clin Invest. 2000; 105(1):3–7 doi:10.1172/JCI9083
This article Copyright © 2000, The American Society for Clinical Investigation
Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

Structure of the Bcr-Abl gene. The Philadelphia chromosome is formed by a reciprocal translocation between chromosomes 9 and 22. Potential breakpoints are indicated by arrows. This resulting translocation replaces the first exon of c-abl with sequences from the Bcr gene.

Copyright © 2011 American Society for Clinical Investigation.
The JCI is the publication of the ASCI, an honor society of physician-scientists.
Copying, redistribution, and other usage policies